MedTrace Logo

Shame, Resilience and Well-being After Intimate Partner Violence: an Intervention Study With Replicated Single-Subject Design.

NCT07618754 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-06-01

No results posted yet for this study

Summary

The EMBER protocol is a health care method that is designed to increase resilience, in order to improve well-being and overall health in women who have experienced violence by a partner. This study explores whether the EMBER intervention works in this way. Eight participants will take part in the EMBER program and complete questionnaires every week during the intervention. The researchers will compare the timeline for the intervention to how resilience levels change. They will also check whether changes in resilience are linked to changes in health and well-being.

Conditions

  • Intimate Partner Violence
  • Resilience, Psychological

Interventions

OTHER

Resilience enhancing intervention, individual format

A 4-step, Resilience-focused intervention based on the Resilience Portfolio Model, administered in individual format.

OTHER

Resilience enhancing intervention, group format

A 4-step, Resilience-focused intervention based on the Resilience Portfolio Model, administered in group format.

Sponsors & Collaborators

  • Uppsala University

    lead OTHER

Principal Investigators

  • Carolina Överlien, Professor · The National Centre for Knowledge on Men's Violence Against Women, Uppsala university

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2030-05-31
Completion
2030-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07618754 on ClinicalTrials.gov